Beneficial effects of sodium glucose co-transporter 2 inhibitors (SGLT2i) on heart failure and cardiovascular death in patients with type 2 diabetes might be due to their off-target effects on cardiac metabolism
Details
The content you want is available to Zendy users.Already have an account? Click here. to sign in.